

21.05.18

# ASX ANNOUNCEMENT

ASX Market Announcements  
Australian Securities Exchange Limited  
10<sup>th</sup> Floor, 20 Bond Street  
SYDNEY NSW 2000

## RESIGNATION OF DIRECTOR – MATHEW RATTY

The Company announces that Mr Mathew Ratty tendered his resignation as director of Admedus Limited on 20 May 2018. Mr Ratty recently became Chief Executive Officer for another ASX listed company. Consistent with industry customs, due to the increased workload from this and his other commitments, he felt unable to dedicate the time needed to fulfil his role as non-executive director.

Accordingly, Mr Ratty will not stand for re-election at Admedus' Annual General Meeting on 24 May 2018.

Mr Ratty stated "I have been very impressed with the milestones this company has hit and the speed at which they have been achieved. The Company is on solid ground and has a great future ahead of it. I will continue to remain a strong supporter of the Company through my material holding in the Company and have further demonstrated this with my recent commitment to participate in the \$6 million Placement, further increasing my investment."

Admedus Chairman, Mr John Seaberg, thanked Mr Ratty for the valued contribution he has made since joining the Admedus Board, and more recently his support and assistance with the \$6 million Placement. "We have been fortunate to have Mat's counsel whilst on our board and we look forward to his continued engagement as a major shareholder. We wish him well in his new leadership role."

The Company will commence its search for an additional Australian based director to replace Mr Ratty.

Attached is an Appendix 3Z (Final Director's Interest Notice) for Mr Ratty.

**ENDS**

**Admedus Limited**  
ABN 35 088 221 078  
**Registered Office**  
Level 9  
301 Coronation Drive  
Milton QLD 4064

**Customer Service**  
T 1300 550 310  
F 1300 880 398  
**International**  
T: +61 8 9266 0100  
F: +61 8 9266 0199

E: [info@admedus.com](mailto:info@admedus.com)  
W: [www.admedus.com](http://www.admedus.com)

**Brisbane • Minneapolis**  
**Zurich • Singapore**

**Background:****ADAPT®**

ADAPT® treated tissue has been scientifically proven to more closely mimic the characteristics of normal human tissue which promotes a more tolerant immune response and improved tissue ingrowth. Clinically-superior ADAPT® tissue products are the only ones to have achieved a decade without calcification or degradation. With the potential for a product lifespan free from calcification, physicians can potentially intervene across a broader age spectrum and provide their patients with a solution for life.

**About Admedus Limited**

Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Website: [www.admedus.com](http://www.admedus.com)

Facebook: [www.facebook.com/Admedus](http://www.facebook.com/Admedus)

Twitter: @Admedus

*For more information, please contact:*

Admedus Limited

Barbara Ferres

+61 7 3152 3216

[communications@admedus.com](mailto:communications@admedus.com)

**Admedus Limited**  
ABN 35 088 221 078

**Registered Office**  
Level 9  
301 Coronation Drive  
Milton QLD 4064

**Customer Service**  
T 1300 550 310  
F 1300 880 398

**International**  
T: +61 8 9266 0100  
F: +61 8 9266 0199

E: [info@admedus.com](mailto:info@admedus.com)  
W: [www.admedus.com](http://www.admedus.com)

**Brisbane • Minneapolis**  
**Zurich • Singapore**

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Admedus Limited</b>
<b>ABN</b>	<b>35 088 221 078</b>

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Mathew Ratty
<b>Date of last notice</b>	7 December 2016
<b>Date that director ceased to be director</b>	20 May 2018

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
-----------------------------------------

+ See chapter 19 for defined terms.

## Appendix 3Z

### Final Director's Interest Notice

---

#### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b> Note: Provide details of the circumstances giving rise to the relevant interest	<b>Number &amp; class of securities</b>
MC Management Group Pty Ltd	(a) 10,434,373 Ordinary Shares (b) 190,000 Unlisted Warrants \$0.79 exp 22/12/2020

#### Part 3 – Director's interests in contracts

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>No. and class of securities to which interest relates</b>	

---

+ See chapter 19 for defined terms.